FDA Approvals - Santarus Submits New Drug Application to FDA for UCERIS (budesonide)
Santarus Submits New Drug Application to FDA for UCERIS (budesonide) Tablets
Santarus, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking market approval for UCERIS Tablets 9 mg for the induction of remission of mild to moderate active ulcerative colitis.